HAPLOIDENTICAL STEM CELL TRANSPLANTATION
Clinical trials for HAPLOIDENTICAL STEM CELL TRANSPLANTATION explained in plain language.
Never miss a new study
Get alerted when new HAPLOIDENTICAL STEM CELL TRANSPLANTATION trials appear
Sign up with your email to follow new studies for HAPLOIDENTICAL STEM CELL TRANSPLANTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for sickle cell patients: drug combo may prevent transplant failure
Disease control Recruiting nowThis study tests whether adding the drug ruxolitinib to a standard stem cell transplant can lower the chance of graft failure in children and young adults (ages 12-45) with severe sickle cell disease. About 24 participants will receive the treatment and be followed for 2 years. T…
Matched conditions: HAPLOIDENTICAL STEM CELL TRANSPLANTATION
Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New drug aims to stop deadly immune attack after stem cell transplant
Disease control Recruiting nowThis study tests an experimental drug called BPC2001 to prevent acute graft-versus-host disease (aGVHD) in 50 adults receiving a half-matched stem cell transplant for blood cancers. Participants get BPC2001 plus standard care, and researchers track how many develop aGVHD by day 1…
Matched conditions: HAPLOIDENTICAL STEM CELL TRANSPLANTATION
Phase: PHASE2 • Sponsor: BioPhoenix Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 14:01 UTC